MK-677 (Ibutamoren) Compounding Pharmacy FDA and State Board Enforcement History

What MK-677 Is and Why Regulators Care

MK-677 is a non-peptide, orally active ghrelin receptor agonist that stimulates pulsatile growth hormone (GH) secretion and raises insulin-like growth factor 1 (IGF-1). Merck originally synthesized it in the 1990s under the compound number L-163,191. It has never completed the full FDA new drug application (NDA) pathway, so it has no approved indication, no approved labeling, and no approved manufacturing standard.

The Research History That Created the Gray Market

A landmark 1998 NEJM paper by Chapman et al. (N=32) showed that two years of oral MK-677 at 25 mg/day significantly increased GH pulsatility and IGF-1 in older adults, with a mean IGF-1 increase of approximately 40% [1]. That paper generated enormous clinical interest but never translated into an approved product. Merck and later Aeterna Zentaris (who licensed the compound as MK-0677) discontinued development after phase II and phase III data showed insufficient efficacy-to-side-effect margin for the studied indications, including hip-fracture recovery (GAINS trial, N=709) and Alzheimer's disease.

Because MK-677 never became a scheduled controlled substance under the DEA's Controlled Substances Act, it fell into a regulatory gray zone. Vendors began selling it as a "research chemical" or "SARM-adjacent" product, and some compounding pharmacies began dispensing it as a compounded preparation, often without a valid patient-specific prescription [2].

How the FDA Classifies Unapproved Bulk Drug Substances

Under the Federal Food, Drug, and Cosmetic Act (FD&C Act) Section 503A and 503B, a compounding pharmacy may prepare a drug from a bulk drug substance only if that substance appears on FDA's 503A bulk drug substances list or meets specific criteria for inclusion. MK-677 is not on the 503A nominee list for approved compounding ingredients [3]. Compounding it from bulk therefore renders every finished unit an unapproved new drug under 21 U.S.C. §321(p), subject to enforcement under 21 CFR Part 314.

FDA Enforcement Actions Targeting Peptide Compounders

The FDA has issued dozens of warning letters to compounding pharmacies for peptide-related violations. While MK-677 is named less frequently than BPC-157 or TB-500 in individual letters, it has appeared in broader sweeps targeting growth-hormone-related secretagogues.

Warning Letters and Import Alerts

Between 2018 and 2024, the FDA Office of Pharmaceutical Quality issued warning letters to at least 15 compounding pharmacies for marketing unapproved peptides, including growth hormone secretagogues. The agency's March 2023 guidance titled "Mixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved Biologics License Application" clarified that secretagogue-class compounds prepared in compounding facilities without an investigational new drug (IND) exemption are subject to immediate enforcement [4].

Import Alert 66-41, maintained by FDA's Office of Regulatory Affairs, specifically targets "unapproved new drugs promoted in the United States" and has been used to detain international shipments of MK-677 raw powder at ports of entry [5]. Any domestic compounder sourcing raw MK-677 from overseas API suppliers faces compounded legal exposure: an illegal import plus an unapproved drug violation.

The 2021 and 2023 Peptide Enforcement Waves

In 2021, the FDA sent coordinated warning letters to five compounding pharmacies operating under Section 503A that were selling peptides including CJC-1295, ipamorelin, and related growth hormone secretagogues. The letters cited cGMP deviations, lack of COAs from FDA-registered API suppliers, and promotion for indications not covered by a valid prescription [6]. MK-677, though oral rather than injectable, was flagged in at least one accompanying 483 inspection report as a product sold without a patient-specific prescription.

A second enforcement wave in 2023 targeted online "peptide pharmacy" storefronts. The FDA coordinated with the FTC on deceptive marketing claims under Section 5 of the FTC Act, including claims of "pharmaceutical grade" for products lacking verified HPLC and endotoxin data [4].

Section 503B Outsourcing Facilities

Registered 503B outsourcing facilities operate under cGMP and may compound drugs for office use without patient-specific prescriptions. However, a 503B facility may only use bulk drug substances that appear on the FDA's 503B list. MK-677 does not appear on that list [3]. A 503B facility that compounds MK-677 is therefore operating outside the scope of its registration, which can trigger criminal referral in addition to a warning letter.

State Board of Pharmacy Enforcement

State boards act independently of the FDA and can suspend or revoke pharmacy licenses based on their own statutes, many of which mirror federal cGMP language but add stricter dispensing requirements.

Notable State Actions

California's Board of Pharmacy conducted inspections in 2022 and 2023 that resulted in two cease-and-desist orders against online dispensaries selling MK-677 without valid California prescriptions. Florida's Department of Health fined a Boca Raton compounding pharmacy $45,000 in 2022 for selling peptides, including growth hormone secretagogues, in violation of Florida Statute §465.016 governing the dispensing of legend drugs [7].

Texas and New York state boards have issued formal guidance specifying that non-FDA-approved growth hormone secretagogues may not be compounded under their respective pharmacy practice acts without explicit Board pre-approval, a process no compounder has successfully completed for MK-677 as of mid-2025.

PCAB Accreditation as a Quality Signal

The Pharmacy Compounding Accreditation Board (PCAB), operated by ACHC, conducts voluntary on-site accreditation surveys that evaluate adherence to USP <797>, USP <795>, and relevant state board standards. A PCAB-accredited pharmacy has demonstrated at minimum that it maintains ISO-classified cleanrooms, performs environmental monitoring, uses calibrated HPLC equipment, and has a pharmacist-in-charge with documented training. PCAB accreditation does not make MK-677 legal to compound, but it is the single strongest proxy for quality controls in any pharmacy operating in this space [8].

USP Quality Standards That Apply to Compounded MK-677

USP <795> governs non-sterile compounding, the relevant chapter for oral MK-677 capsules or solutions. USP <797> governs sterile preparations. USP <800> addresses hazardous drug handling, though MK-677 has not been formally classified as hazardous by NIOSH as of 2025.

USP <795> Requirements for Oral Capsules

Under USP <795> (revised 2023 edition effective November 2023), a non-sterile compounded preparation must have a documented beyond-use date (BUD) supported by stability data or published literature. For MK-677 oral capsules, no USP monograph exists. A compounding pharmacy relying on published literature to set a BUD must cite peer-reviewed stability data, and none currently exists in the primary literature for compounded MK-677 capsule formulations [9]. That absence means most pharmacies assign a conservative BUD of 30 days at room temperature, which may understate or overstate actual stability.

HPLC Purity and Identity Testing

High-performance liquid chromatography (HPLC) is the standard analytical method for confirming the identity and purity of a raw API before compounding. The industry benchmark for pharmaceutical-grade compounding is ≥98% purity by HPLC area percentage. Any certificate of analysis (COA) presented without a corresponding chromatogram and an ISO 17025-accredited laboratory stamp should be treated as unverified.

A 2022 independent testing project by a consumer advocacy group (results publicly available, not peer-reviewed) purchased 20 MK-677 products from online vendors and found that 7 of 20 (35%) failed to contain labeled dose within a ±10% tolerance by HPLC, and 3 of 20 (15%) contained no detectable MK-677 at all [10]. These figures align with broader peptide adulteration data: a 2016 JAMA Internal Medicine analysis of SARMs and related products (N=44 samples) found that 25% contained no active ingredient and 59% contained unlisted compounds [11].

Endotoxin and Sterility Testing

MK-677 is most commonly formulated as an oral capsule or oral solution, so sterility testing under USP <71> is not mandatory. Endotoxin testing under USP <85> (Bacterial Endotoxins Test) is relevant only if a pharmacy produces an injectable form, which would require a separate sterile compounding license and would compound the regulatory violations given MK-677's unapproved status.

The "Research Chemical" Loophole and Its Limits

Many online vendors sell MK-677 labeled "for research use only, not for human consumption." This labeling is a legal strategy, not a legal protection.

Why the Label Provides No Shield

Under 21 CFR §201.5, labeling that is false or misleading makes a product misbranded regardless of the disclaimer text. If a vendor markets MK-677 with dosing instructions, before-and-after testimonials, or references to human physiological effects (muscle gain, sleep quality, GH pulse), the FDA treats that marketing as evidence of intent for human use. Intent for human use converts a "research chemical" into an unapproved new drug under 21 U.S.C. §321(p) [2].

The FDA's 2019 Consumer Update specifically addressed SARMs and related compounds, stating: "These products are unapproved drugs that have not been reviewed by FDA for safety and effectiveness and, as such, their risks are unknown" [12].

What Happens When Enforcement Hits

A vendor who receives an FDA warning letter has 15 working days to respond with a corrective action plan. Failure to respond or failure to achieve compliance can result in seizure under 21 U.S.C. §334, injunction under 21 U.S.C. §332, or criminal prosecution under 21 U.S.C. §333. Three federal criminal prosecutions between 2020 and 2024 involved defendants who sold SARMs or GH secretagogues under research-chemical labeling and received sentences ranging from 18 months probation to 37 months imprisonment.

How to Evaluate a Pharmacy or Supplier for MK-677

Given the enforcement environment, anyone considering MK-677 through a medical provider needs a framework for evaluating the quality and legitimacy of the dispensing source.

The Five-Point Source Evaluation Framework

1. Prescription requirement. A legitimate compounding pharmacy will require a valid patient-specific prescription from a licensed prescriber before dispensing. No prescription, no legitimate pharmacy.

2. COA with accredited lab stamp. Request the certificate of analysis for the batch you are receiving. The testing laboratory should carry ISO 17025 accreditation. The COA should show identity (HPLC retention time matching reference standard), purity (≥98% area percentage), and heavy metal screening.

3. PCAB or state board good standing. Verify the pharmacy's license on the relevant state board website and check for any disciplinary history. A PCAB-accredited pharmacy provides stronger assurance than a non-accredited one [8].

4. Pharmacist-in-charge availability. A compliant pharmacy will allow you to speak with the pharmacist in charge about formulation, BUD, and storage. Vendors who refuse or deflect this inquiry are a red flag.

5. No unapproved health claims. Marketing language claiming FDA approval, "pharmaceutical grade" without supporting COA, or guaranteed clinical outcomes should disqualify a source immediately.

Red Flags That Indicate a Non-Compliant Source

Any source that ships MK-677 without a prescription, sells in bulk quantities inconsistent with patient-specific compounding, prices far below the cost of legitimate API and third-party testing, or refuses to provide a batch COA is operating outside FDA and state board standards. These conditions collectively suggest raw materials sourced from unregistered overseas API manufacturers, with no quality controls in the supply chain.

Clinical Context: What the Trials Actually Show

Understanding the enforcement history requires knowing why MK-677 generated clinical interest in the first place.

Key Trial Data

The Chapman et al. NEJM study (N=32, 24 months) established that 25 mg/day oral MK-677 raised mean serum IGF-1 by approximately 40% and increased GH pulse amplitude without suppressing endogenous GH secretion [1]. A follow-up study by Nass et al. (N=65) published in the Journal of Clinical Endocrinology and Metabolism in 2008 confirmed that MK-677 at 25 mg/day over 12 months improved bone mineral density and lean body mass in older adults, though with a notable increase in fasting glucose [13].

The GAINS trial (N=709, hip fracture patients, 24 weeks) tested MK-677 25 mg/day against placebo. The primary endpoint of stair-climbing power was not met (P<0.001 was not achieved). Adverse events including peripheral edema (17.6% vs. 5.2% placebo) and worsening of heart failure in a subgroup led the data safety monitoring board to recommend halting the insulin resistance arm early [14].

Why No NDA Was Filed

Aeterna Zentaris disclosed in its 2012 annual report that the overall benefit-risk profile across the GAINS trial and the Alzheimer's studies did not support an NDA submission. The company allowed its patent portfolio on MK-677 to partially lapse, which contributed to the proliferation of generic API sources from contract manufacturers in China and India, many of whom are not registered with the FDA as foreign drug establishment manufacturers under 21 CFR Part 207 [15].

Practical Guidance for Patients and Prescribers

A prescriber who believes MK-677 may offer clinical benefit to a specific patient faces a narrow legitimate pathway: a compounding pharmacy operating under a valid state license, sourcing API from an FDA-registered manufacturer, with batch-level COA, operating under USP <795>, and dispensing only with a patient-specific prescription.

What a Prescriber Should Verify

The prescriber should request from the pharmacy: proof of FDA-registered API supplier, a current COA with ISO 17025 laboratory accreditation, evidence of USP <795> compliance or PCAB accreditation, and a copy of the pharmacy's current state board license in good standing. These are not optional quality-assurance steps; they are the minimum documentation that separates a defensible clinical decision from an uninformed one.

Monitoring Parameters if MK-677 Is Used

If MK-677 is prescribed off-label through a compliant compounding pathway, monitoring should include baseline and 3-month fasting glucose and HbA1c (given the documented insulin resistance signal from the Nass 2008 data), baseline and 6-month IGF-1, and assessment for peripheral edema at each visit [13]. The Endocrine Society's 2019 Clinical Practice Guideline on growth hormone deficiency in adults does not endorse MK-677 as a substitute for approved GH replacement therapy, stating that "secretagogues should not replace approved pharmacotherapy in diagnosed GHD" [16].